Genetic Testing Falls Flat in Large Patient Drug Trials
By Susan Young,
MIT Technology Review
| 11. 19. 2013
In recent years, DNA variants in two different genes have been linked to how much blood thinner a patient needs. Researchers have developed algorithms to predict a proper dose based on those genes as well characteristics such as weight and age. But now new research suggests these formulas may not actually help doctors determine the right dose.
Blood thinners can be difficult to prescribe because each patient can respond differently depending on their physical characteristics, their diet, and other medications they take. Based on that information, doctors tailor the dosage so it is high enough to prevent clotting but not so high that it causes internal bleeding. Once an initial dose is given, blood tests can help a doctor tune in to the best dose.
The hope has been that doctors might be better able to hit the right dose by looking at genes known to affect a patient’s response to the drugs—an approach called pharmacogenetics. Many experts have promoted this approach and some small patient trials have offered hope, writes
Bruce Furie, a Harvard specialist in bleeding and...
Related Articles
By Pallab Gosh and Gwyndaf Hughes, BBC News | 06.26.2025
Work has begun on a controversial project to create the building blocks of human life from scratch, in what is believed to be a world first.
The research has been taboo until now because of concerns it could lead to...
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...